{"id":"NCT02943577","sponsor":"Naurex, Inc, an affiliate of Allergan plc","briefTitle":"A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-02","primaryCompletion":"2018-10-26","completion":"2018-11-21","firstPosted":"2016-10-24","resultsPosted":"2019-11-13","lastUpdate":"2019-11-13"},"enrollment":429,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"Rapastinel","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rapastinel 450 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 milligrams (mg) compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.","primaryOutcome":{"measure":"Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Study","timeFrame":"Baseline and 3 Weeks","effectByArm":[{"arm":"Placebo","deltaMin":-4.1,"sd":0.64},{"arm":"Rapastinel 450 mg","deltaMin":-5.1,"sd":0.66}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2398"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":40,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.allerganclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":209},"commonTop":["Headache"]}}